Arrowhead Pharmaceuticals 04280A100 3/14/2024 Advisory Vote to Approve Executive Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Senseonics Holdings, Inc. 81727U105 5/22/2024 Advisory approval of the compensation of the Company?s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Procept BioRobotics Corporation 74276L105 6/04/2024 Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Aldeyra Therapeutics, Inc. 01438T106 6/04/2024 To approve, on a non-binding, advisory basis, the compensation of Aldeyra Therapeutics, Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Adicet Bio, Inc. 007002108 6/5/2024 To ratify, on a non-binding advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Adicet Bio, Inc. 007002108 6/5/2024 To ratify, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Marker Therapeutics, Inc. 57055L206 6/6/2024 To approve, on an advisory basis, the compensation of the Company?s named executive officers, as disclosed in this proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Xencor, Inc. 98401F105 6/13/2024 To approve,by non-binding advisory vote, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Altimmune Inc 02155H200 9/28/2023 Balloting on Proposal 3, to approve, on an advisory basis, the compensation of the Company?s named executive officers as disclosed in the proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Altimmune Inc 02155H200 9/28/2023 Balloting on Proposal 4, to approve, on an advisory basis, on the frequency of future advisory votes on the compensation of the Company?s named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Gyre Therapeutics, Inc. 403783103 8/29/2023 To approve, by non-binding advisory vote, the compensation of Catalyst?s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Gyre Therapeutics, Inc. 403783103 8/29/2023 To conduct an advisory vote on the frequency of future advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Standard Biotools, Inc. 34385P108 6/27/2024 To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 0 NONE Meira GTx Holdings plc G59665102 6/6/2024 To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 6641064 0 FOR 6641064 FOR Meira GTx Holdings plc G59665102 6/6/2024 To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 6641064 0 1YEAR 6641064 AGAINST Fate Therapeutics, Inc. 31189P102 6/7/2024 To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 3379064 0 FOR 3379064 FOR Protagonist Therapeutics Inc. 74366E102 6/20/2024 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 2449183 0 FOR 2449183 FOR